Clinical trials: Neuropathy, Diabetic
Foot Ulcer, Diabetic
GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers
The objective of the study is to compare the efficacy of weekly GrafixPRIME® administration to an Active Comparator in patients with chronic DFUs in a randomized, single-blind study.
- Trial name
- NCT02675855
- Testing
- GrafixPRIME®, Dressing Application, Off-loading (walking boot)
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Osiris Therapeutics
Diabetic Neuropathy
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
Phase 2/3 open-label trial to assess the safety and tolerability of long-term treatment with lacosamide (SPM 927) in subjects with painful diabetic neuropathy.
- Trial name
- NCT00235443
- Testing
- lacosamide
- Where
- 84 sites in United States
- Volunteers
- 451 people
- Sponsor
- UCB Pharma
Diabetic Neuropathy, Painful
Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain
This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain.
- Trial name
- NCT00266643
- Testing
- duloxetine hydrochloride
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 205 people
- Sponsor
- Eli Lilly and Company
Neuropathic Pain
Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain
The trial is designed to evaluate the efficacy and tolerability of carbamazepine in neuropathic pain in diabetic patients
- Trial name
- NCT01089855
- Testing
- Carbamazepine
- Where
- Morocco
- Volunteers
- 123 people
- Sponsor
- Novartis
Diabetic Foot, Lower Extremity Wound
Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers
In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers.
- Trial name
- NCT05087758
- Testing
- Matrion, Conventional Care Wound Management
- Where
- 8 sites in United States
- Volunteers
- 108 people
- Sponsor
- LifeNet Health
Herpes Zoster, Neuralgia
An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain
This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114
- Conditions
- Herpes Zoster, Neuralgia, Pain, HIV Infections
- Trial name
- NCT00089557
- Testing
- Capsaicin Dermal Patch
- Sponsor
- NeurogesX
Diabetes Mellitus, Painful Distal Symmetric Sensorimotor Polyneuropathy
Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy
The difference between active treatment and placebo in a clinical trial of an analgesic appears to depend on a variety of factors other than the actual efficacy of the drug itself, including various aspects of study design and…
- Trial name
- NCT01770964
- Testing
- Pregabalin, Training Type A, Training Type B
- Where
- 6 sites in United States
- Volunteers
- 90 people
- Sponsor
- Analgesic Solutions
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
The purpose of this clinical investigation is to evaluate the safety and efficacy of Amnion/Chorion/Amnion allograft , Amnion/Chorion allograft, and/or Amnion/Amnion allograft, plus Standard of Care (SOC) each versus SOC alone in…
- Trial name
- NCT06681428
- Testing
- Allograft
- Where
- 9 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tides Medical
Diabetic Foot, Diabetic Foot Ulcer
Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
The study will evaluate the safety and performance of Symphony™ versus Standard of Care (SOC) in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Chronic Foot Ulcer
- Trial name
- NCT06035536
- Testing
- Symphony™ plus Off-loading, Wound Dressing comprising of calcium alginate Fibracol
- Where
- 11 sites in United States
- Volunteers
- 143 people
- Sponsor
- Aroa Biosurgery Limited
Diabetic Neuropathy, Painful
PDN Post Market, Multicenter, Prospective, Global Clinical Study
The purpose of this post-market study is to evaluate the real-world experience of Nevro's Spinal Cord Stimulation (SCS) therapy in patients with chronic, intractable leg pain due to painful diabetic neuropathy (PDN).
- Trial name
- PDN-PM (NCT05301816)
- Testing
- Spinal Cord Stimulator (SCS)
- Where
- 8 sites in United States
- Volunteers
- 497 people
- Sponsor
- Nevro Corp
Diabetic Polyneuropathy
Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
The primary objectives of the study are to evaluate the efficacy and safety of three doses of MCC-257 in patients with mild to moderate diabetic polyneuropathy
- Trial name
- NCT00307749
- Testing
- MCC-257
- Volunteers
- 420 people
- Sponsor
- Tanabe Pharma Corporation
Acute and Chronic Wounds, Pressure Ulcers
Clinical Evaluation of the SNaP Wound Care System
The purpose of this study is to assess the efficacy of design improvements of the Spiracur SNaP Wound Care System. This study prospectively evaluates the safety and efficacy of current and new design iterations of components of…
- Conditions
- Acute and Chronic Wounds, Pressure Ulcers, Trauma Wounds, Diabetic Foot Ulcers
- Trial name
- NCT01113658
- Testing
- SNaP Wound Care System
- Where
- 2 sites in United States
- Sponsor
- 3M
Foot Ulcer, Diabetic
Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers
The goal of this clinical trial is to determine the safety of DERMASEAL for the treatment of non-healing, neuropathic diabetic foot ulcers. The main outcome measure is safety.
- Trial name
- NCT05586542
- Testing
- DERMASEAL, Plasma Film, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Vitruvian Medical Devices, Inc.
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH303 (NCT00738062)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 103 people
- Sponsor
- Chelsea Therapeutics
Painful Diabetic Neuropathies
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.
- Trial name
- NCT01475786
- Testing
- Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202)
- Where
- 17 sites in United States, South Korea
- Volunteers
- 104 people
- Sponsor
- Helixmith Co., Ltd.
Diabetic Foot Ulcers
Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer
This is an open-label, active-control, multicentre, parallel group, randomised and dose-finding efficacy and safety study. Compare the efficacy and safety of BioChaperone PDGF-BB applied at 12.5 µg/cm² every two days for up to 20…
- Trial name
- NCT01098357
- Testing
- Biochaperone PDGF-BB Low dose, Biochaperone PDGF-BB High dose, Regranex
- Where
- 7 sites in India
- Volunteers
- 192 people
- Sponsor
- Virchow Group
Diabetic Peripheral Neuropathy
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild…
- Trial name
- NCT01681290
- Testing
- CBX129801
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Cebix Incorporated
Diabetic Foot Ulcer
A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer
The present clinical trial is designed to assess the effectiveness of BioChaperone PDGF-BB applied at 4 µg/cm² every other day for up to 20 weeks and associated to Standard of Care as compared to Standard of Care alone for the…
- Trial name
- NCT02236793
- Testing
- BioChaperone PDGF-BB, Standard of Care
- Where
- 32 sites in India
- Volunteers
- 252 people
- Sponsor
- Adocia
Diabetic Foot Ulcer of Neuropathic Origin
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan).
- Trial name
- TRANS-South (NCT01217463)
- Testing
- Trafermin 0.01% spray
- Where
- 24 sites in Czechia, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Olympus Biotech Corporation
Diabetic Foot, Chronic Foot Ulcer
Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers
The study will evaluate the efficacy of SynPath™, a synthetic dermal matrix, in the treatment of diabetic foot ulcers in subjects with diabetes mellitus versus Standard of Care treatment.
- Conditions
- Diabetic Foot, Chronic Foot Ulcer, Wound Healing, Foot Ulcer
- Trial name
- DFUs (NCT05506215)
- Testing
- SynPath Acellular Dermal Matrix plus Off-loading Device, Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- PolyNovo Biomaterials Pty Ltd.